| Patient | Jesse Owens |
|---|---|
| Date of birth | 1913-09-12 |
| Identifiers | MRN HR-ML042-SYN-TD; SSN (made up) 000-42-8319 |
| Document date | 2026-11-01 |
| Author | Clarence Whitfield-Arroyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit: shared decision-making for lung cancer screening, same-day low-dose CT showing a suspicious left upper lobe nodule, and tobacco treatment. Concerns: He wants to know quickly and plainly whether the spot on the scan is cancer, and what can be done; He has smoked for 35 years, has failed to stop twice on his own, and worries that stopping now is pointless; No doctor had offered him a lung scan before; he wants the same care anyone else would get, without delay; He wants to keep speaking to young people and to keep walking every morning. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 | 0.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7 | Oral route | 1979-05-26 to 1979-06-01 | completed | S |
| Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse | 1 mg twice daily after food | Oral route | 1979-06-02 | active | S |
| Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial) | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cycles | Day 1 every 21 days for three cycles | Intravenous route | 1979-06-03 to 1979-07-15 | completed | S |
| Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last | One tablet daily | Oral route | 1979-05-26 to 1979-08-05 | completed | S |
| Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed) | 1000 mcg once; a second dose was not due before pemetrexed ended | Intramuscular route | 1979-05-26 to 1979-05-26 | completed | S |
| Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose | 4 mg twice daily for three days around each cycle | Oral route | 1979-06-02 to 1979-07-16 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy | 8 mg every 8 hours as needed | Oral route | 1979-06-03 to 1979-07-31 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets every 8 hours as needed for pain after surgery | 1000 mg every 8 hours as needed | Oral route | 1979-08-22 to 1979-09-15 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Shared decision-making visit for lung cancer screening with a decision aid (benefits, false positives, overdiagnosis, radiation, and the need for yearly scans and for tobacco treatment); he chose to be screened | 1979-05-11 to 1979-05-11 | completed | S |
| Low-dose CT of the chest without contrast for lung cancer screening (first screen): solid, spiculated 2.9 cm nodule in the apicoposterior segment of the left upper lobe; enlarged left hilar lymph node 1.6 cm in short axis; mild centrilobular emphysema in both upper lobes; coronary artery calcification, moderate; Lung-RADS 4X (category 4B with additional features of malignancy) | 1979-05-11 to 1979-05-11 | completed | S |
| Chest X-ray, posteroanterior and lateral: the left upper lobe nodule is smaller than on the screening CT; no new opacity, consolidation or ground-glass change; no effusion | 1979-07-06 to 1979-07-06 | completed | S |
| Advance care planning conversation, about 25 minutes, with his consent | 1979-10-21 to 1979-10-21 | completed | S |
| FDG PET-CT: avid left upper lobe nodule, 2.9 cm (SUVmax 9.8); avid left interlobar (11L) node, 1.6 cm (SUVmax 6.1); no avid mediastinal, supraclavicular or contralateral node; no distant uptake. The infrarenal abdominal aorta measures 2.1 cm | 1979-05-14 to 1979-05-14 | completed | S |
| MRI of the brain with contrast: no metastases | 1979-05-15 to 1979-05-15 | completed | S |
| Endobronchial ultrasound with systematic needle aspiration of stations 4R, 4L, 7, 10L and 11L under moderate sedation: adenocarcinoma in 11L (TTF-1 positive); 4R, 4L, 7 and 10L negative with adequate lymphocytes; PD-L1 (22C3) tumor proportion score 40 percent; tissue next-generation sequencing (reported in six days, with concordant plasma testing): KRAS G12C mutation, STK11 and KEAP1 wild type; no EGFR, ALK, ROS1, BRAF V600E, MET exon 14, RET, NTRK or HER2 alteration | 1979-05-19 to 1979-05-19 | completed | S |
| Thoracic multidisciplinary tumor board (thoracic surgery, medical and radiation oncology, pulmonology, radiology, pathology, nurse navigator): resectable cT1c N1 M0 stage IIB adenocarcinoma, no EGFR or ALK alteration; recommends three cycles of nivolumab with platinum doublet chemotherapy, restaging, then lobectomy | 1979-05-21 to 1979-05-21 | completed | S |
| Pulmonary function tests: spirometry and DLCO (FEV1 2.71 L, 86 percent predicted; FEV1/FVC 0.73; DLCO 86 percent predicted). Predicted postoperative values after left upper lobectomy (14 of 19 segments remaining): FEV1 63 percent and DLCO 63 percent | 1979-05-26 to 1979-05-26 | completed | S |
| Pulmonary rehabilitation as prehabilitation during chemoimmunotherapy: 16 supervised sessions of aerobic and strength training with breathing exercises, twice weekly | 1979-06-08 to 1979-08-14 | completed | S |
| Restaging CT of the chest and upper abdomen with contrast after three cycles: left upper lobe nodule 1.3 cm (from 2.9 cm); left interlobar node 0.8 cm (from 1.6 cm); no new nodule, node, effusion or ground-glass change; no liver or adrenal lesion | 1979-07-31 to 1979-07-31 | completed | S |
| Video-assisted thoracoscopic left upper lobectomy with systematic mediastinal (stations 4L, 5, 6, 7, 8, 9) and hilar lymph node dissection; three days in hospital without complications. Pathology: ypT1a N0 (0 of 16 nodes; treatment effect without viable tumor in the 11L node), 0.7 cm residual adenocarcinoma with 6 percent viable tumor (major pathologic response), margins clear (R0) | 1979-08-19 to 1979-08-22 | completed | S |
| Pulmonary rehabilitation after lobectomy: a 12-week program, twice weekly, started | 1979-10-05 to 1979-10-05 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1979-05-26 | Pneumococcal conjugate vaccine PCV20, before chemoimmunotherapy | completed | S |
| 1979-10-21 | Influenza vaccine, high-dose, this season | completed | S |
| 1979-10-21 | COVID-19 mRNA vaccine, this season's formula | completed | S |
| 1979-10-21 | Respiratory syncytial virus vaccine, single dose | completed | S |
| 1979-10-21 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| about 1920 | Pneumonia at about age 7, during an epidemic in Alabama, from which he nearly died; a sickly, underweight childhood in poverty | D (CLM-0002) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| brother | Died in childhood during the epidemic in which he had pneumonia; cause not recorded in the cited source | D (CLM-0002) | |
| sister | Died in childhood during the same epidemic; cause not recorded in the cited source | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| He wants to know quickly and plainly whether the spot on the scan is cancer, and what can be done | active | S |
| He has smoked for 35 years, has failed to stop twice on his own, and worries that stopping now is pointless | active | S |
| No doctor had offered him a lung scan before; he wants the same care anyone else would get, without delay | active | S |
| He wants to keep speaking to young people and to keep walking every morning | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13.1 on 1979-07-06; Leukocytes [#/volume] in Blood by Automated count 5.4 on 1979-07-06; Platelets [#/volume] in Blood by Automated count 176 on 1979-07-06; Sodium [Moles/volume] in Serum or Plasma 138 on 1979-08-05; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1979-08-05; Creatinine [Mass/volume] in Serum or Plasma 1 on 1979-09-30; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M 84 on 1979-09-30; Glucose [Mass/volume] in Serum or Plasma 92 on 1979-09-30; Calcium [Mass/volume] in Serum or Plasma 9.3 on 1979-08-05; Albumin [Mass/volume] in Serum or Plasma 4 on 1979-08-05; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1979-09-30; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1979-09-30; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 90 on 1979-08-05; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 1979-09-30; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1979-10-21; Neutrophils [#/volume] in Blood by Automated count 3.2 on 1979-07-06; Thyrotropin [Units/volume] in Serum or Plasma 4.6 on 1979-09-30; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 on 1979-09-30; Cortisol [Mass/volume] in Serum or Plasma 12.9 on 1979-08-05; FEV1 2.71 on 1979-05-26; FEV1 measured/predicted 86 on 1979-05-26; FEV1/FVC 0.73 on 1979-05-26; Diffusion capacity.carbon monoxide 23.6 on 1979-05-26; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 1979-05-26; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 7 on 1979-05-26; Total score [Mini-Cog] 5 on 1979-10-21; Total score [AUDIT-C] 2 on 1979-10-21 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked | resolved | confirmed | R91.1 | S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit. |
| Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration | active | confirmed | C34.12 | S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable. |
| Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine | resolved | confirmed | F17.210 | S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission. |
| Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
| After thoracoscopic left upper lobectomy with mediastinal and hilar lymph node dissection: ypT1a N0 (0 of 16 nodes), R0, major pathologic response (6 percent residual viable tumor) | active | confirmed | Z90.2 | S — Synthetic consequence of the synthetic operation. |
| Nicotine dependence, cigarettes, in early remission: no cigarettes since day 1 of cycle 1, about four months, on varenicline | active | confirmed | F17.211 | S — Synthetic modern entry linked to his documented smoking. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1979-05-11 | Hemoglobin [Mass/volume] in Blood | 15.1 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1979-05-11 | Leukocytes [#/volume] in Blood by Automated count | 8.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-05-11 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1979-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1979-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1979-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1979-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1979-05-11 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1979-05-11 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1979-05-11 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 1979-05-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 1979-05-11 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 8-48 U/L | Normal | S |
| 1979-05-11 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 84 | U/L | 40-129 U/L | Normal | S |
| 1979-05-11 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1979-05-11 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1979-05-26 | Hemoglobin [Mass/volume] in Blood | 14.9 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1979-05-26 | Leukocytes [#/volume] in Blood by Automated count | 8.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-05-26 | Neutrophils [#/volume] in Blood by Automated count | 5.2 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1979-05-26 | Platelets [#/volume] in Blood by Automated count | 258 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1979-05-26 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1979-05-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1979-05-26 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 1979-05-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 7-55 U/L | Normal | S |
| 1979-05-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-48 U/L | Normal | S |
| 1979-05-26 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1979-05-26 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1979-05-26 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1979-05-26 | Cortisol [Mass/volume] in Serum or Plasma | 13.8 | ug/dL | Morning (8 a.m.) reference interval | Normal | S |
| 1979-05-26 | FEV1 | 2.71 | L | Lower limit of normal for his age and height (GLI 1965) | Normal | S |
| 1979-05-26 | FEV1 measured/predicted | 86 | % | >=80% | Normal | S |
| 1979-05-26 | FEV1/FVC | 0.73 | {ratio} | Below 0.70 after bronchodilator indicates airflow obstruction | Normal | S |
| 1979-05-26 | Diffusion capacity.carbon monoxide | 23.6 | mL/min/mm[Hg] | Lower limit of normal for his age and height; predicted 27.4 | Normal | S |
| 1979-05-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1979-05-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S | ||
| 1979-06-24 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1979-06-24 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-06-24 | Neutrophils [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1979-06-24 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1979-06-24 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1979-06-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1979-06-24 | Glucose [Mass/volume] in Serum or Plasma | 101 | mg/dL | 70-99 mg/dL | High | S |
| 1979-06-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-55 U/L | Normal | S |
| 1979-06-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 | U/L | 8-48 U/L | Normal | S |
| 1979-06-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1979-06-24 | Thyrotropin [Units/volume] in Serum or Plasma | 2.6 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1979-06-24 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1979-06-24 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1979-08-05 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 13.5-17.5 g/dL | Low | S |
| 1979-08-05 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-08-05 | Neutrophils [#/volume] in Blood by Automated count | 3.6 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1979-08-05 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1979-08-05 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1979-08-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1979-08-05 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1979-08-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 74 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1979-08-05 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 1979-08-05 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1979-08-05 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 1979-08-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 1979-08-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-48 U/L | Normal | S |
| 1979-08-05 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 90 | U/L | 40-129 U/L | Normal | S |
| 1979-08-05 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1979-08-05 | Thyrotropin [Units/volume] in Serum or Plasma | 6.8 | m[IU]/L | 0.4-4 mIU/L | High | S |
| 1979-08-05 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1979-08-05 | Cortisol [Mass/volume] in Serum or Plasma | 12.9 | ug/dL | Morning (8 a.m.) reference interval | Normal | S |
| 1979-08-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1979-09-30 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 13.5-17.5 g/dL | Low | S |
| 1979-09-30 | Leukocytes [#/volume] in Blood by Automated count | 7 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-09-30 | Neutrophils [#/volume] in Blood by Automated count | 4.3 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1979-09-30 | Platelets [#/volume] in Blood by Automated count | 246 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1979-09-30 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1979-09-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1979-09-30 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 1979-09-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 1979-09-30 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-48 U/L | Normal | S |
| 1979-09-30 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1979-09-30 | Thyrotropin [Units/volume] in Serum or Plasma | 4.6 | m[IU]/L | 0.4-4 mIU/L | High | S |
| 1979-09-30 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1979-09-30 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1979-07-06 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 13.5-17.5 g/dL | Low | S |
| 1979-07-06 | Leukocytes [#/volume] in Blood by Automated count | 5.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-07-06 | Neutrophils [#/volume] in Blood by Automated count | 3.2 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1979-07-06 | Platelets [#/volume] in Blood by Automated count | 176 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1979-10-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1979-10-21 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 1979-10-21 | Total score [AUDIT-C] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1979-05-11 | Body height | 178 | cm | S |
| 1979-05-11 | Body weight | 77 | kg | S |
| 1979-05-11 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 1979-05-11 | Systolic blood pressure | 134 | mm[Hg] | S |
| 1979-05-11 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1979-05-11 | Heart rate | 78 | /min | S |
| 1979-05-11 | Respiratory rate | 16 | /min | S |
| 1979-05-11 | Body temperature | 36.7 | Cel | S |
| 1979-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1979-05-26 | Body height | 178 | cm | S |
| 1979-05-26 | Body weight | 76.6 | kg | S |
| 1979-05-26 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 1979-05-26 | Systolic blood pressure | 130 | mm[Hg] | S |
| 1979-05-26 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1979-05-26 | Heart rate | 80 | /min | S |
| 1979-05-26 | Respiratory rate | 16 | /min | S |
| 1979-05-26 | Body temperature | 36.6 | Cel | S |
| 1979-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1979-06-24 | Body height | 178 | cm | S |
| 1979-06-24 | Body weight | 75.8 | kg | S |
| 1979-06-24 | Body mass index (BMI) [Ratio] | 23.9 | kg/m2 | S |
| 1979-06-24 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1979-06-24 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1979-06-24 | Heart rate | 74 | /min | S |
| 1979-06-24 | Respiratory rate | 16 | /min | S |
| 1979-06-24 | Body temperature | 36.6 | Cel | S |
| 1979-06-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1979-08-05 | Body height | 178 | cm | S |
| 1979-08-05 | Body weight | 75.2 | kg | S |
| 1979-08-05 | Body mass index (BMI) [Ratio] | 23.7 | kg/m2 | S |
| 1979-08-05 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1979-08-05 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1979-08-05 | Heart rate | 72 | /min | S |
| 1979-08-05 | Respiratory rate | 14 | /min | S |
| 1979-08-05 | Body temperature | 36.5 | Cel | S |
| 1979-08-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1979-09-30 | Body height | 178 | cm | S |
| 1979-09-30 | Body weight | 74.6 | kg | S |
| 1979-09-30 | Body mass index (BMI) [Ratio] | 23.5 | kg/m2 | S |
| 1979-09-30 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1979-09-30 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1979-09-30 | Heart rate | 76 | /min | S |
| 1979-09-30 | Respiratory rate | 16 | /min | S |
| 1979-09-30 | Body temperature | 36.6 | Cel | S |
| 1979-09-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1979-07-06 | Body height | 178 | cm | S |
| 1979-07-06 | Body weight | 75.6 | kg | S |
| 1979-07-06 | Body mass index (BMI) [Ratio] | 23.9 | kg/m2 | S |
| 1979-07-06 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1979-07-06 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1979-07-06 | Heart rate | 84 | /min | S |
| 1979-07-06 | Respiratory rate | 16 | /min | S |
| 1979-07-06 | Body temperature | 37.6 | Cel | S |
| 1979-07-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1979-10-21 | Body height | 178 | cm | S |
| 1979-10-21 | Body weight | 75 | kg | S |
| 1979-10-21 | Body mass index (BMI) [Ratio] | 23.7 | kg/m2 | S |
| 1979-10-21 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1979-10-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1979-10-21 | Heart rate | 70 | /min | S |
| 1979-10-21 | Respiratory rate | 16 | /min | S |
| 1979-10-21 | Body temperature | 36.6 | Cel | S |
| 1979-10-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1979-05-11 | New patient visit: shared decision-making for lung cancer screening, same-day low-dose CT showing a suspicious left upper lobe nodule, and tobacco treatment | finished | S |
| 1979-05-26 | Diagnosis of left upper lobe adenocarcinoma, stage IIB: thoracic oncology consultation, tumor board plan for chemoimmunotherapy before surgery, and start of varenicline | finished | S |
| 1979-06-24 | Day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed: toxicity, immune-related adverse event monitoring, smoking abstinence and prehabilitation | finished | S |
| 1979-08-05 | After three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparation | finished | S |
| 1979-09-30 | Six weeks after left upper lobectomy: pathology, surveillance plan, tobacco remission and pulmonary rehabilitation | finished | S |
| 1979-07-06 | Same-day sick visit for a cold during chemoimmunotherapy | finished | S |
| 1979-10-21 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Referral to thoracic oncology: consultation within two weeks to review the screening CT, PET-CT and EBUS results with him and plan treatment | completed | GL-NCCN-NSCLC-2026, GL-CMID-2026 | S |
| Work-up of the Lung-RADS 4X nodule without delay: FDG PET-CT and brain MRI with contrast this week, then endobronchial ultrasound with systematic sampling of mediastinal and hilar nodes (at least stations 4R, 4L and 7, and any PET-avid node), with enough tissue for PD-L1 and comprehensive next-generation sequencing (EGFR, ALK, ROS1, BRAF, KRAS, MET exon 14, RET, NTRK, HER2) and plasma testing in parallel; nurse navigator to track each date | completed | GL-USPSTF-LUNG-2021, GL-ACCP-SCREEN-2021, GL-ACR-LUNGRADS-2022, GL-NCCN-NSCLC-2026, GL-ACCP-STAGING-2013 | S |
| Tobacco treatment at every visit: brief advice, varenicline offered with a quit date, the Arizona quitline and counseling; stopping smoking improves outcomes even after a lung cancer diagnosis | completed | GL-USPSTF-TOB-2021, GL-CMID-2026 | S |
| Equity safeguards: a nurse navigator, written results and next steps at each visit, transport and cost help offered, and time from scan to treatment tracked against the goal | completed | GL-ALDRICH-2019, GL-BACH-1999 | S |
| Distress and depression screening at each visit, plain information he can share, and advance care planning when he is ready | completed | GL-CMID-2026 | S |
| Chemoimmunotherapy before surgery: nivolumab 360 mg with carboplatin (AUC 5) and pemetrexed 500 mg/m2 every three weeks for three cycles, with folic acid, vitamin B12 and dexamethasone premedication, hepatitis B, hepatitis C and HIV tests first, and restaging CT before surgery | completed | GL-NCCN-NSCLC-2026, GL-CHECKMATE816-2022 | S |
| Immune-related adverse event monitoring: TSH, free T4, liver tests, creatinine, glucose and blood count before each cycle, morning cortisol at baseline and before surgery, and a written list of warning symptoms with a 24-hour oncology line | completed | GL-ASCO-IRAE-2021, GL-CMID-2026 | S |
| Physiologic evaluation for lobectomy (spirometry and DLCO with predicted postoperative values) and prehabilitation: a pulmonary rehabilitation program during chemotherapy | completed | GL-ACCP-PHYS-2013, GL-CMID-2026 | S |
| Thoracoscopic left upper lobectomy with systematic mediastinal and hilar lymph node dissection after restaging shows response and no new disease | completed | GL-NCCN-NSCLC-2026, GL-ACCP-EARLY-2013 | S |
| After surgery: no further systemic therapy after a major pathologic response, by shared decision; history, examination and chest CT every six months for two to three years, then yearly low-dose CT; pulmonary rehabilitation after surgery; the KRAS G12C result kept on file for any recurrence | completed | GL-NCCN-NSCLC-2026, GL-ASCO-SURV-2020, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| PET-CT, brain MRI, EBUS staging, tissue diagnosis, PD-L1 and comprehensive biomarker results and a tumor board plan within three weeks of the screening CT | 1979-05-26 | completed | PET-CT in three days, brain MRI in four, EBUS in eight, tumor board in ten; PD-L1 and tissue sequencing back by the consultation, 15 days after the scan | S |
| Stop smoking completely before treatment starts and stay stopped | 1979-09-30 | completed | No cigarettes since day 1 of cycle 1, about four months; varenicline continued to complete 24 weeks | S |
| Three cycles of chemoimmunotherapy before surgery without a delay of more than one week and without an immune-related adverse event of grade 2 or higher | 1979-08-05 | completed | Three cycles on schedule; only a grade 1 rise in TSH, monitored without treatment | S |
| Complete resection (R0) with systematic lymph node dissection within six weeks of the last cycle | 1979-09-30 | completed | Thoracoscopic left upper lobectomy five weeks after cycle 3; R0; major pathologic response | S |
| Back to walking 3 km most mornings by three months after surgery | 1979-09-30 | completed | Walking 2 km a day six weeks after surgery and starting pulmonary rehabilitation | S |